A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

NCT03729245 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

623

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL: bempegaldesleukin
DRUG: sunitinib
BIOLOGICAL: nivolumab
DRUG: cabozantinib

Sponsor

Nektar Therapeutics

Collaborators

[object Object]